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MicroRNAExpression Profiles in Serous Ovarian Carcinoma
Eun Ji Nam,1Heejei Yoon,2 Sang Wun Kim,1Hoguen Kim,2 Young Tae Kim,1 Jae Hoon Kim,1
Jae Wook Kim,3 and Sunghoon Kim1
Abstract Purpose:AlthoughmicroRNAs have recently been recognized as riboregulators of gene expres-
sion, little is known about microRNA expression profiles in serous ovarian carcinoma.We
assessed the expression of microRNA and the association between microRNA expression and
the prognosis of serous ovarian carcinoma.
Experimental Design: Twenty patients diagnosed with serous ovarian carcinoma and eight
patients treated for benign uterine disease between December 2000 and September 2003 were
enrolled in this study. The microRNA expression profiles were examined using DNA microarray
and Northern blot analyses.
Results:SeveralmicroRNAswere differentially expressed in serous ovarian carcinoma compared
with normal ovarian tissues, including miR-21, miR-125a, miR-125b, miR-100, miR-145, miR-16,
andmiR-99a, whichwere each differentially expressed in >16 patients. In addition, the expression
levels of somemicroRNAs were correlated with the survival in patients with serous ovarian carci-
noma. Higher expression of miR-200, miR-141, miR-18a, miR-93, and miR-429, and lower
expressionof let-7b, andmiR-199awere significantly correlatedwith apoor prognosis (P < 0.05).
Conclusion:Our results indicate that dysregulation of microRNAs is involved in ovarian carcino-
genesis and associated with the prognosis of serous ovarian carcinoma.
Ovarian cancer is the most lethal of the gynecologic malignan-
cies, but relatively little is known about themolecular genetics of
its initiation and progression. Epithelial ovarian cancer, which
accounts for 90% of ovarian cancer, is a heterogeneous group of
neoplasms and is divided into histologic subgroups, each with
their own underlying molecular genetic events: serous, mucin-
ous, endometrioid, clear cell, Brenner, and undifferentiated
carcinomas (1, 2). Among them, the serous type accounts for
75% to 80% of epithelial ovarian carcinomas. High grade serous
ovarian carcinoma has a high incidence of TP53 (3), HER-2/
ERBB2 (4), and AKT2 gene mutations (5) but a low incidence of
KRAS and BRAF gene mutations (6). Nevertheless, the primary
genetic alterations associated with serous ovarian carcinoma
remain to be identified.
MicroRNAs (miRNA) are noncoding, single-stranded RNAs of
f22 nucleotides in length that constitute a novel class of gene
regulators. miRNAs function as guide molecules by base paring
with the mRNAs partially complementary to the miRNAs in
miRNA-associated effector complexes (7). The binding of
miRNAs to their target mRNAs leads to translational repression
or decreases the stability of the mRNA (7, 8). miRNAs control
various biological processes, including cell differentiation, cell
proliferation, apoptosis, stress resistance, and fatmetabolism (9).
SomemiRNAs possess oncogenic or tumor suppressor activity.
The first study documenting abnormalities in miRNA expression
in tumors identified miR-15a and miR-16-1 , which are located
in a frequently deleted region in B-cell chronic lymphocytic
leukemia (10). In a subsequent study, the miRNAs were found
to suppress BCL2 , an antiapoptic gene (11). The let-7 family,
which is down-regulated in lung cancer when RAS is frequently
mutated (12), negatively regulates RAS (13). miR-155 is
overexpressed in Burkitt’s lymphoma (14), breast cancer (15),
and lung cancer (16). Its overexpression in transgenic mice leads
to preleukemic pre–B-cell proliferation (17). miR-372 and
miR-373 cooperate with oncogenic RAS in the cellular
transformation of testicular germ cell tumors (18). All these
findings suggest that altered miRNA expression contributes
to tumorigenesis.
miRNA expression profiles show unique expression patterns
according to the clinical features in several cancers, including
chronic lymphocytic leukemia (19), breast cancer (15), pan-
creatic cancer (20), and lung cancer (12, 16), suggesting that
some miRNAs could be used as diagnostic and prognostic
markers. Of note, Lu et al. (21) found that miRNA expression
profiling is much better for classifying poorly differentiated
samples than mRNA expression profiling. Therefore, miRNA
profiling may have a crucial clinical application.
In this study, we investigated the miRNA expression profiles
in serous ovarian carcinoma and attempted to identify miRNAs
capable of predicting the clinical prognosis.
Imaging, Diagnosis, Prognosis
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Materials andMethods
Patients and tumor tissues. After obtaining informed consent and
performing surgery at the Yonsei University College of Medicine (Seoul,
Korea), samples of primary epithelial ovarian cancer were snap frozen
in liquid nitrogen and stored at -80jC. The histopathologic diagnoses
were determined using the WHO criteria, and the tumor histotype was
serous cystadenocarcinoma in all patients. Twenty-eight samples were
used for this study, including 20 serous ovarian carcinomas and
8 normal ovarian tissues. The clinical data and patient information are
shown in Supplementary Table S1. Nine patients whose cancer
progressed within 12 mo from the initiation of platinum-based
combination chemotherapy were defined as the chemoresistant-disease
group, whereas 11 patients whose cancer did not recur for >24 mo were
defined as the chemosensitive-disease group. Progression was defined
as the appearance of a new metastatic site that was not present at the
initiation of primary chemotherapy or an abnormal CA-125 value with
an increase of >25% over the previous level. Progression-free survival
was defined as the interval from the initiation date of primary
chemotherapy to the date of progression. Overall survival was
calculated from the initiation date of primary chemotherapy until the
date of death or the last follow-up visit.
miRNA microarrays. The frozen samples were homogenized in
TRIzol reagent (Invitrogen) using an Omni-Mixer Homogenizer (Omni
International). Total RNA was then isolated according to the
manufacturer’s instructions. Total RNA from eight normal ovarian
tissues was pooled and used as a common reference for miRNA
expression. For the miRNA microarray study, 50 Ag of total RNA were
further processed to enrich the miRNA using a Purelink miRNA
Isolation kit (Invitrogen). DNA oligonucleotide probes from the
mirVana miRNA Probe Set (Ambion), which contains 314 human, 49
mouse, and 14 rat miRNA genes, were printed on coated glass slides in
duplicate (Digital Genomics); 50 Amol/L probes were resuspended with
3 SSC and spotted on AttayIt SuperEpoxy2 (TeleChem) under 55%
humidity using the ArrayIt SpotBot (TeleChem). The spot diameter
was 100 Am. The slides were rehydrated and blocked in a solution
containing 100 mmol/L ethanolamine, 1 mol/L Tris (pH 9.0),
and 0.1% SDS for 20 min at 50jC and then rinsed thoroughly with
water and spun dry. Purified miRNAs were labeled using a mirVana
miRNA Labeling kit (Ambion) and amine-reactive Cy5 or Cy3 dyes,
as recommended by the manufacturer. Poly(A) polymerase and a
mixture of unmodified and amine-modified nucleotides were first used
to append a polynucleotide tail to the 3¶ end of each miRNA. The
amine-modified miRNAs were then cleaned and coupled to NHS-
ester–modified Cy5 or Cy3 dye (Amersham Biosciences). The RNA
from normal ovarian tissues and cancer tissues was labeled with Cy3
and Cy5 dye, respectively. Slides were hybridized for 12 to 16 h at 42jC
in sealed cassettes under controlled humidity.
Data analysis. After hybridization, the slides were washed and dried
before performing a high-resolution scan on a GenePix 4000B Array
Scanner (Axon Instruments). The scanned images were analyzed with
GenePix software version 3.0 (Axon Instruments) to obtain gene
expression ratios. Transformed data were normalized using the Lowess
procedure (Supplementary Fig. S1; ref. 22) and subjected to analysis
using the Significance Analysis of Microarrays software program
(SAM, Version 1.10) and clustering analysis (23). The clustering
analysis was done using the Cluster and TreeView programs available
online.4 Abnormal data were flagged during the GenePix software
analysis and these numerical data were excluded from the SAM analysis.
Missing data were input using the average of 10 nearest neighbors. For
the clinical data analysis, only the miRNAs differentially expressed in
more than three patients were selected to decrease possible technical
errors. Fisher’s exact test and the Mann-Whitney U test were used to
evaluate which miRNAs could discriminate the chemosensitive and
chemoresistant groups (ver. 12.0; SPSS, Inc.). For the selected miRNAs,
receiver operating characteristics curve analysis was used to assess the
diagnostic accuracy of each miRNA. Survival analysis was used to
compare patients with or without specific miRNAs in terms of
progression-free and overall survival. The Kaplan-Meier method was
used to estimate survival curves, and the log-rank statistic was used to
test the equality of the survival functions between the patients with or
without specific miRNA.4
Northern blot analysis. Twenty-microgram RNA samples were
separated on 15% Tris-borate EDTA urea acrylamide gels (Bio-Rad),
and then transferred onto Hybond-N+ membranes (Amersham
Biosciences) and subjected to UV cross-linking. The oligonucleotides
with a sequence complementing the mature miRNAs were labeled using
polynucleotide kinase and [g-32P]ATP. The miRNAs were hybridized in
ULTRAhyb-oligo (Ambion) at 37jC overnight. The membranes were
washed thrice with 2 SSC + 0.1% SDS for 5 min at room temperature
then exposed to a phosphor screen for 24 to 72 h and imaged using a
BAS-2500 (Fujifilm). The signal intensities were measured using the
program TINA2.0 (TINA). The blots were stripped with 0.1% SSC +
0.1% SDS at 80jC for 30 min and were reprobed. 5S RNA was used as
a loading control.
Results
Distinct miRNA signatures in serous ovarian cancer, compared
with normal ovarian tissues. To identify miRNAs differentially
expressed in serous ovarian cancer compared with the
corresponding normal tissues, we used a customized miRNA
microarray that contained 314 human miRNAs from the
miRNA Registry (24). We analyzed the miRNA expression4 http://rana.lbl.gov
Table 1. Differentially expressed miRNAs with >2-
fold change in tumor versus normal ovarian
tissues in at least 12 of 20 ovarian cancer patients
miRNA Up* (%) Down* (%) Meanc M F SD
(median)
miR-145 0/20 0 17/20 85 -3.20 F 1.13 (-3.38)
miR-125b 0/20 0 19/20 95 -2.74 F 0.80 (-2.59)
miR-100 0/20 0 18/20 90 -2.57 F 1.08 (-2.47)
miR-99a 0/20 0 18/20 90 -2.48 F 0.93 (-2.37)
miR-26a 0/20 0 15/20 75 -2.17 F 0.78 (-1.92)
miR-10b 1/20 5 12/20 60 -1.99 F 1.34 (-1.87)
miR-143 1/20 5 14/20 70 -1.70 F 1.06 (-1.85)
miR-214 0/20 0 12/20 60 -2.08 F 0.93 (-1.81)
let-7b 1/20 5 13/20 65 -1.57 F 1.06 (-1.63)
miR-199a-AS 2/20 10 11/20 55 -1.36 F 1.34 (-1.48)
miR-29a 1/20 5 12/20 60 -1.50 F 1.15 (-1.46)
miR-125a 2/20 10 16/20 80 -1.18 F 0.97 (-1.26)
miR-93 14/20 70 0/20 0 1.68 F 0.53 (1.56)
miR-23b 11/20 55 1/20 5 1.63 F 1.63 (2.02)
miR-20a 12/20 60 0/20 0 2.12 F 0.65 (2.10)
miR-27a 12/20 60 1/20 5 1.85 F 1.16 (2.22)
miR-16 16/20 80 1/20 5 2.49 F 1.65 (2.29)
miR-23a 11/20 55 1/20 5 1.77 F 1.52 (2.36)
miR-200a 12/20 60 0/20 0 2.58 F 0.79 (2.71)
miR-200b 14/20 70 0/20 0 2.84 F 0.92 (2.82)
miR-21 17/20 85 0/20 0 2.89 F 1.20 (2.88)
miR-200c 14/20 70 0/20 0 3.19 F 0.95 (3.00)
miR-141 14/20 70 0/20 0 2.91 F 0.87 (3.02)
*Frequency of up or down-regulated miRNAs, which were consid-
ered differentially expressed if their M values are >1.0 or lower
than (-)1.0.
cM, value of log2 (Cy5/Cy3).
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profiles of 20 serous ovarian cancer tissues using a two-color
system. We used pooled miRNAs from normal tissues as a
common reference for each cancer case. After normalization,
an ‘‘MA plot’’ was used to represent the data, where M = log2
(Cy5/Cy3). The confidence of the signal was confirmed using
SAM analysis (23). miRNAs were considered differentially
expressed if their M values were >1.0 or <-1.0. Twenty-three
miRNAs were differentially expressed in at least 12 of the 20
serous ovarian cancers (Table 1). The up-regulated miRNAs
(n = 11) were miR-200a, miR-200b, miR-200c, miR-20a,
miR-21, miR-23a, miR-23b, miR-27a, miR-141, miR-16 , and
miR-93 . The down-regulated miRNAs (n = 12) were miR-214,
miR-26a, miR-29a, let-7b, miR-100, miR-10b, miR-125a, miR-
125b, miR-143, miR-145, miR-199a-AS , and miR-99a . Of these
miRNAs, the most frequently up-regulated miRNA was miR-21
(17 of 20 cases), and the most frequently down-regulated
miRNA was miR-125b (19 of 20 cases). Although the cancer
specimens were obtained from different patients, the expres-
sion trends of the miRNAs were homogenous across almost
all cases. miRNA families displaying one or two base
differences, such as miR-200a, miR-200b , and miR-200c ,
showed similar expression profiles in the same ovarian cancer
patients (Fig. 1).
Validation of the microarray results. To validate the micro-
array results, Northern blots of the differentially expressed
miRNAs were done independently. We chose miR-200c,
miR-93, miR-141, let-7b, miR-99a , and miR-125b , which were
differentially expressed between the normal ovarian tissues and
serous ovarian cancer tissues (Fig. 2). In agreement with
the microarray results, miR-200c, miR-93 , and miR-141 were
up-regulated, whereas let-7b, miR-99a , and miR-125b were
down-regulated in ovarian carcinoma. We quantified the band
intensity of each miRNA and calculated the relative expression
ratios after normalizing each band intensity to 5S RNA. The
average correlation between the Northern blot results and
microarray data were 0.791 (P < 0.001; Supplementary Fig. S2).
We found that let-7b had a lower correlation between the two
analyses compared with the other miRNAs tested, which might
have resulted from the high ability of the let-7 family to cross-
hybridize, as reported previously (21). Overall, however, the
microarray data were good enough to warrant further analyses
in a clinical setting.
miRNA signatures are associated with the prognosis of serous
ovarian carcinoma. Next, we wanted to determine whether the
miRNA expression profiles could distinguish chemosensitive
cases from chemoresistant cases to assess the effect of miRNA
expression on prognosis. The majority of the cases were
separated into the two groups using an unsupervised hierar-
chical cluster analysis (Fig. 1). However, seven cases did not
separate well based on the gene expression profiles of the
selected miRNAs. Therefore, Fisher’s exact test was done using
the binomial variable whether the miRNA was differentially
expressed or not. miR-199a and ambi-miR-7039 were signifi-
cantly down-regulated in the chemoresistant group (P < 0.05;
Supplementary Table S2). Ambi-miR-7039 are newly identified
human miRNAs called Ambi-miR miRNAs. Based on the
sequences provided by the company, ambi-miR-7039 is a small
nucleolar RNA. Therefore, we excluded ambi-miR-7039 from
Fig. 1. Unsupervised hierarchical clustering
analysis of miRNAs that exhibited a >2-fold
increase or decrease in at least three cases
of serous ovarian carcinoma.The level of
miRNA expression is color-coded. Red,
higher miRNA expression; green, lower
miRNA expression; black, no difference. S,
chemosensitive disease; R, chemoresistant
disease.
Imaging, Diagnosis, Prognosis
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further analysis. To evaluate the usefulness of miRNAs for
detecting chemoresistant disease, we did a receiver operating
characteristics analysis on the selected miRNAs to detect
the recurrence of persistent ovarian cancer. Down-regulated
miR-199a had the greatest area under the curve (0.763;
Supplementary Table S2). As a result, the down-regulation of
miR-199a could be a reliable marker for predicting chemo-
resistant disease.
Second, we investigated the correlation between the miRNA
expression profile and survival. Kaplan-Meier analysis was
done, and the median survival based on the expression of
miRNA is shown in Table 2. Higher expression of miR-200a,
miR-200b, miR-200c, miR-141, miR-18a, miR-93 , and miR-429 ,
and lower expression of ambi-miR-7039, let-7b , and miR-199a
were significantly correlated with decreased progression-free
survival and overall survival (log-rank test, P < 0.05; Table 2).
As shown in Fig. 3, tumors with high expression of miR-200a
had a median overall survival of 27.5 months (95% confidence
interval, 22.8-46.0) compared with 61.0 months (95% confi-
dence interval, 43.5-67.8) for those with no significant
expression (P = 0.0054).
Discussion
We identified 23 miRNAs whose expression is significantly
deregulated in serous ovarian carcinoma compared with
normal ovarian tissues. These miRNAs may be used to
distinguish serous ovarian cancer from normal ovarian tissue.
While our article was being reviewed, a study of miRNA
expression profiling in ovarian cancer was published by Iorio
and colleagues (25). Half of the miRNAs that we identified
(Table 1) are seen in their list of miRNAs aberrantly expressed.
They include the most significantly altered miRNAs in both
studies: miR-200a/b/c, miR-141, miR-21, miR-145, miR-99a,
let-7 , and miR-125b . This concordance further supports our
findings and relevance of these miRNAs to ovarian cancer.
The most consistently up- and down-regulated miRNAs were
miR-21 and miR-125b , respectively. miR-21 is also up-regulated
in other cancers such as glioblastoma (26), breast cancer (15),
and cholangiocarcinoma cell lines (27). In recent reports, the
up-regulation of miR-21 was associated with an antiapoptotic
effect on tumor growth (27). The inhibition of miR-21 using
antisense oligonucleotides increased the expression level of
PTEN (27), a negative regulator of the phosphatidylinositol-
3-OH kinase–AKT signaling pathway, and decreased Bcl-2
(28), an antiapoptotic gene, resulting in inducing apoptosis. A
loss of heterozygosity of PTEN was seen in f30% of serous
ovarian cancer without additional somatic mutations (29).
Serous ovarian cancer may acquire an antiapoptotic phenotype
by inactivating PTEN genetically and up-regulation of miR-21 .
miR-125b was implicated in differentiation (30), cell
proliferation, and mobility (31). Receptor tyrosine kinases
ERBB2 and ERBB3 were shown to be targets of miR-125a/b
(31). Overexpression of miR-125a/b in an ERBB2-positive
breast cancer cell line impaired cell growth and mobility
Table 2. Median survival of serous ovarian carcinoma patients according to the miRNA expression profiling
Median progression-free survival F SD (mo) Median overall survival F SD (mo)
Significant
expression*
No significant
expression
Pc Significant
expression*
No significant
expression
Pc
miR-200a 11.0 F 20.7 54.5 F 24.8 0.0302 27.5 F 18.3 61.0 F 14.5 0.0054
miR-200b 11.0 F 22.9 54.5 F 20.5 0.0183 29.5 F 18.8 61.0 F 11.2 0.0334
miR-200c 11.0 F 22.9 54.5 F 20.5 0.0163 29.5 F 18.8 61.0 F 11.2 0.0183
miR-27a 12.0 F 22.0 55.0 F 25.2 0.0677 30.0 F 18.2 57.0 F 17.2 0.0669
miR-31 9.5 F 11.9 45.0 F 25.2 0.1118 26.5 F 18.7 53.5 F 18.7 0.1104
ambi-miR-7039 7.5 F 15.6 53.5 F 21.7 0.0059 27.0 F 19.5 55.5 F 15.5 0.0136
let-7b 11.0 F 24.4 54.0 F 21.9 0.0194 29.5 F 18.8 57.0 F 7.0 0.0149
miR-141 11.0 F 23.0 54.5 F 20.5 0.0163 29.5 F 18.8 61.0 F 11.2 0.0183
miR-18a 10.5 F 18.1 46.0 F 25.7 0.0472 27.5 F 17.2 55.5 F 19.1 0.0345
miR-182 10.0 F 21.8 40.0 F 25.2 0.1104 25.0 F 16.7 56.0 F 18.1 0.0575
miR-199a 9.5 F 21.8 54.0 F 20.1 0.0164 27.0 F 20.4 56.5 F 11.7 0.0181
miR-429 9.0 F 17.3 52.0 F 23.9 0.0083 29.0 F 17.7 55.0 F 18.2 0.0186
miR-93 11.0 F 23.0 54.5 F 20.5 0.0163 29.5 F 18.8 61.0 F 11.2 0.0183
*Significant expression of miRNA was defined if M value >1 or <-1.
cLog-rank test gave significant P values (P < 0.05).
Fig. 2. Northern blot of selected miRNAs.miR-200c, miR-93, andmiR-141
were up-regulated, whereas let-7b, miR-99a, andmiR-125b were down-regulated
in serous ovarian carcinomas, in agreement with the microarray results. C1-C3,
three different normal ovarian tissues; the same samples were pooled as a
common reference in the microarray experiment. S, chemosensitive disease;
R, chemoresistant disease.
miRNAExpression Profiles in Serous Ovarian Carcinoma
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capability (31). Frequent overexpression or amplification of
ERBB2 was reported inf20% of serous ovarian cancers (2, 32).
Because the chromosome 11q23-24 for miR-125b-1 is one of
the regions most frequently deleted in breast, ovarian, and lung
cancers (33), correlation between the overexpression of ERBB2
or ERBB3 and loss of miR-125a/b loci might exist. In addition
to miR-125b , low levels of let-7 were seen frequently in our
cases. Some of them might be related to oncogenic mutations
in KRAS , accounting for 35% of low-grade serous ovarian
carcinoma (2), based on reciprocal relationship between let-7
and its target gene RAS (13). In addition to oncogenes ERBB2,
BRBB3, and RAS , additional target genes of miR-125b and let-7
might be responsible for the high frequency of their down-
regulation in serous ovarian cancer.
Contrary to a previous report (11), we observed increased
levels of miR-15 and miR-16 , which are miRNAs with tumor-
suppressing properties. Their lower levels were associated with
high antiapoptotic BCL2 protein in chronic lymphocytic
leukemia (11). This discrepancy could have resulted from the
activity of specific miRNAs in different tissues or cellular
contents (34). For example, the miR-17 cluster was amplified in
human non–small cell lung cancer (35), whereas the cluster
was frequently deleted in hepatocellular carcinoma (36).
Our findings suggest that the most reliable predictive marker
for chemoresistant disease was the down-regulation ofmiR-199a
(area under the curve, 0.763), which is located on chromosome
19p13.2. Web-based computational approaches (TargetScan,
PicTar-Vert, and MiRanda) predict hundreds of potential targets
of miR-199a , including discoidin domain receptor family
member 1 (DDR1), a gene predicted by at least two of these
methods that contains more than three conserved sites for the
miRNA. DDR1 is a receptor tyrosine kinase activated by various
collagens, and it plays a role in cell attachment, migration,
survival, and proliferation. DDR1 was reported to induce
cyclooxygenase-2 expression resulting in enhanced chemo-
resistance via the nuclear factor-nB pathway (37). However,
further studies are needed to validate the function of thismiRNA.
Ten miRNAs were significantly correlated with patient
survival. miR-199a was also related to patient survival because
clinically, survival might be affected markedly by chemo-
resistance. Notably, of the identified miRNAs (Table 2), five
miRNAs originated from two clustered chromosome regions:
miR-200a, miR-200b , and miR-429 are from chromosome
1p36.33, and miR-200c and miR-141 are from chromosome
12p13.31. The increased expression of miR-200a might
underlie genomic amplification. Frequent chromosomal gains
in that region have been reported in serous ovarian carcinoma
(38, 39). The inhibition of miR-200b increased the sensitivity to
gemcitabine in cholangiocarcinoma cell lines (27), and
thereby, increased expression of miR-200b may result in poor
response to antineoplastic drugs. Moreover, inhibition of
miR-141 using anti–miR-141 decreased cell growth in chol-
angiocarcinoma cell lines (27). Accordingly, these miRNAs
could be a novel target for enhancing chemosensitivity or
inducing cell death in serous ovarian cancer. As a result, we can
predict the prognosis of patients with serous ovarian carcinoma
using the deregulated miRNAs. Although other studies have
examined miRNAs in ovarian cancer (21, 25, 39), to our
knowledge, ours is the first to ascribe a prognostic value to
miRNAs expression profiles in serous ovarian carcinoma.
Overall, our report contributes to the understanding of
miRNA expression profiling and its relationship to tumorigen-
esis in serous ovarian carcinoma. Moreover, some miRNAs are
significantly correlated with the response to chemotherapy and
survival in serous ovarian carcinoma, and could be used as
prognostic markers.
Fig. 3. Kaplan-Meier overall survival curve for patients with serous ovarian
carcinoma based on the expression of miRNAs.The higher expression ofmiR-200a
(A) andmiR-200c (B) was significantly correlated with a shorter overall survival.
The log-rank test gave significant P values (P < 0.05).
Imaging, Diagnosis, Prognosis
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